
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
BBIO | NASDAQ | USD | Real-time | |
1BBIO | Milan | EUR | Real-time | |
2CL | TradeGate | EUR | Delayed |
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Name | Age | Since | Title |
---|---|---|---|
Jennifer E. Cook | 57 | 2019 | Director |
Ronald J. Daniels | 63 | 2020 | Independent Director |
James C. Momtazee | 51 | 2016 | Director |
Randal W. Scott | 65 | 2020 | Independent Director |
Ali J. Satvat | 46 | 2016 | Independent Director |
Andrea John Ellis | 36 | 2021 | Independent Director |
Douglas Adam Dachille | 61 | 2021 | Independent Director |
Hannah A. Valantine | 71 | 2021 | Independent Director |
Wen-Chaun Lo | 62 | 2020 | Independent Director |
Eric M. Aguiar | 61 | 2019 | Independent Director |
Neil Kumar | 45 | 2015 | Co-Founder, CEO & Director |
Fred Hassan | 79 | 2021 | Lead Independent Director |
Frank P. McCormick | 75 | 2019 | Co-Founder, Chairman of Oncology & Director |
Charles J. Homcy | 77 | 2018 | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review